RGEN — Repligen Corporation
$176.93-1.00%
Last close: · regular session
Last 60 sessions
RGEN closed at $176.93 (-1.00%) on Oct 23, 2026. Recent offering filing (424B3, Sep 2026). Float: 53.2M shares. Latest SEC filing: SCHEDULE 13G/A on Oct 7, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for RGEN in the TickerWise workspace.
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Medical - Instruments & Supplies
- Country: US
- Exchange: NASDAQ
- Employees: 1,778
- Website: https://www.repligen.com
Latest SEC filings for RGEN
Latest RGEN news
- Repligen Q3 2026 Earnings Preview Read article
- Repligen to Report Third Quarter 2026 Financial Results Read article
- Repligen Corp (RGEN) Shares Fall 7.7% -- What GF Score of 85 Tells Investors Read article
- Repligen Completes Acquisition of BioLife Solutions Read article
- BioLife Solutions Shareholders Approve Repligen Merger Agreement Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.